A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive

Trial Profile

A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Aug 2017

At a glance

  • Drugs Ixekizumab (Primary) ; Adalimumab
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms SPIRIT-H2H
  • Sponsors Eli Lilly
  • Most Recent Events

    • 01 Aug 2017 Planned End Date changed from 1 Mar 2019 to 21 Jun 2019.
    • 18 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top